Tripair’s Vision for the Future: Simplifying Tricuspid Repair Worldwide

Across the globe, millions of patients living with tricuspid regurgitation (TR) remain untreated. Despite growing awareness of the disease and advances in technology, existing treatment options are often too complex, resource-intensive, or limited to a small number of highly specialized centers. Coramaze is working to change this.

“The vision behind Tripair™ is to develop an intuitive, safe and effective technology based on the genius of enabling simplicity,” said Coramaze’s CEO, Jochen Reinöhl. We will do this by overcoming the current restrictive complexity of both the condition and current treatment options.” By removing procedural barriers, Tripair™ aims to enable broader access to care and offer a life-changing solution to so many patients who currently have no option.

Enabling Simplicity combines deep clinical expertise with thoughtful engineering and a clear understanding of how hospitals deliver care in the real world. Tripair™’s edge-to-spacer system is designed for usability, reproducibility, and scalability, with the goal of making treatment more accessible to physicians and patients alike.

Enabling Simplicity is not just a technical principle; it is a response to a global access challenge. Today, more than 90% of patients with significant TR receive no meaningful therapy. By simplifying tricuspid repair, Tripair™ aims to help bridge that gap and bring treatment to those who need it most.

As Coramaze continues to advance the Tripair™ program, the company is engaging closely with physicians, hospitals, and industry partners to shape a future where tricuspid repair is available beyond specialized centers — and where simplicity drives impact at scale.

In the short video above, Jochen Reinöhl (CEO) and Laurie Hayner (VP Clinical Operations) explain the concept behind Enabling Simplicity. It brings together clinical expertise in tricuspid disease, a precise understanding of physician and hospital needs, and elegant engineering designed for real-world application.

Tripair™ is an investigational device and not commercially available in any geography. The opinions provided are those of the patients and physicians and are not intended to be claims related to the safety, effectiveness, or performance of the device.